Wolfgang Miesbach on The 1st Case of Secondary Malignancy Triggered by Integrated AAV
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”Is there evidence that integrated AAV can trigger oncogenesis in a clinical setting?
First case worldwide with molecular evidence linking AAV integration to human malignancy.
The FDA placed clinical holds on REGENXBIO’s AAV9-based gene therapies after detecting a CNS tumour in a 5-year-old with Hurler syndrome (MPS I).
The case:
Patient: 5-year-old with Hurler syndrome (MPS I)
Therapy: RGX-111 — AAV9 carrying IDUA gene (α-L-iduronidase)
Dose: 5.0×10¹⁰ vg/gram brain mass (~10¹³⁻¹⁴ total)
Route: Intracisternal injection (direct CSF)
Timeline: Brain tumour detected 4 years post-injection
Status: Asymptomatic; surgically resected; progressing developmentally
Critical context: No tumours in 9 other RGX-111 recipients or 32 RGX-121-treated patients (some followed ~7 years).
Pathogenic mechanism:
Finding: AAV integration in resected tumour with PLAG1 proto-oncogene overexpression.
Mechanism: PLAG1 (pleomorphic adenoma gene 1) is normally silenced in adult tissues. AAV integration may have created a promoter substitution event—placing the strong CMV/CB7 promoter near PLAG1, driving ectopic overexpression. This recapitulates the exact mechanism in spontaneous PLAG1-driven tumours (salivary adenomas, lipoblastomas).
Context: At clinical doses (~10¹⁴ vector genomes), even 0.1–1% integration frequency equals millions of integration events per patient.
Implications for haemophilia gene therapy:
Haemophilia therapies target the liver (AAV5/AAV8), not CNS (AAV9)—fundamentally different biology.
Evidence from >500 haemophilia patients treated with gene therapy:
8 cancer cases reported total: NO evidence AAV caused the cancer—
Adult hepatocytes are postmitotic; strong regenerative capacity dilutes integrated genomes
AAV5/AAV8 are liver-selective; minimal CNS penetration
This case increases uncertainty and awareness. Patient awareness and informed consent so importannt:
- Detailed baseline information before treatment
- Explicit shared decision-making
- Long-term surveillance protocols and registries”
Read the full announcement here.
Stay updated with Hemostasis Today.
-
Jun 27, 2026, 01:31Alessio De Rose: Addressing Micronutrient Deficiencies in the Era of GLP-1 Receptor Agonists
-
Jun 27, 2026, 01:21Michelle Sámano Sánchez: Exploring Vitamin C as an Adjunct Therapy for Anemia in Hemodialysis
-
Jun 27, 2026, 01:08Ana Raquel Gotine: The First Pragmatic Clinical Trial on MNPs and Childhood Anemia in Mozambique
-
Jun 27, 2026, 00:56Sherif Badawy: Reflecting on My Time with ASH CRTI
-
Jun 27, 2026, 00:48Zain Khalpey: Why High quality CPR is Only Part of Successful Cardiac Arrest Management
-
Jun 26, 2026, 22:31Wendy Dusenbury: The New Issue of the Stroke Clinician is Now Live
-
Jun 26, 2026, 20:42Ed Watson: When It Happens to You, Stroke Becomes Personal, Immediate, and Life-Changing
-
Jun 26, 2026, 19:45Nathan Connell: Transforming Surgical Care with Tranexamic Acid
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?